Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood (2022) 139 (15): 2347–2354.

https://doi.org/10.1182/blood.2021014472

Published: 2022

Includes: Supplemental data

Journal Articles

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Cornelis N. De Jong, MD, Ellen Meijer, MD PhD, Katerina Bakunina, Erfan Nur, MD PhD, Marinus van Marwijk Kooij, MD PhD, Marco R. de Groot, MD PhD, Michel van Gelder, MD PhD, Johan A. Maertens, MD PhD, Jurgen H.E. Kuball, MD PhD, Dries Deeren, MD PhD, Bronno van der Holt, PhD, Jan J Cornelissen, MD PhD, Annoek E.C. Broers, MD PhD

Blood (2019) 134 (Supplement_1): 1.

https://doi.org/10.1182/blood-2019-124659

Published: 2019

Journal Articles

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

Cornelis N. De Jong, MD, Ellen Meijer, MD PhD, Katerina Bakunina, Erfan Nur, MD PhD, Marinus van Marwijk Kooij, MD PhD, Marco De Groot, MD PhD, Michel Van Gelder, MD PhD, Johan A. Maertens, MD PhD, Jurgen H.E. Kuball, MD PhD, Dries Deeren, MD PhD, Bronno Van Der Holt, PhD, Jan J Cornelissen, MD PhD, Annoek E.C. Broers, MD PhD

Blood (2019) 134 (Supplement_1): 371.

https://doi.org/10.1182/blood-2019-130872

Published: 2019

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blood (2017) 130 (Supplement 1): LBA-5.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-5.LBA-5

Published: 2017

Journal Articles

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, MD PhD, Marie José Kersten, MD, Edo Vellenga, MD, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, MD, Henk M Lokhorst, Annemiek Broyl, MD PhD, Karim Saad Iskander, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3141.

https://doi.org/10.1182/blood.V130.Suppl_1.3141.3141

Published: 2017

Journal Articles

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Blood (2017) 130 (Supplement 1): 2606.

https://doi.org/10.1182/blood.V130.Suppl_1.2606.2606

Published: 2017

Journal Articles

Efficacy of Bone Marrow Derived MSC for Steroid Refractory Acute GVHD Associates with Age and a Defined Molecular Profile of MSC Donors

Lotte van der Wagen, MD, Febilla Fernando, Nagesha Appukudige, PhD, Anke Janssen, MD, Kasper Westinga, Rick Admiraal, MD PhD, Magdalena Lorenowicz, PhD, Paul J. Coffer, PhD Prof, Sacha Zeerleder, PhDMD, Jeroen J. Janssen, MD PhD, Gerwin Huls, MD PhD, Annoek Broers, MD PhD, Walter JFM Van Der Velden, Marinus van Marwijk Kooij, MD PhD, Jaap Jan Boelens, MD PhD, Ineke Slaper-Cortenbach, PhD, Jurgen Kuball, MD

Blood (2017) 130 (Supplement 1): 1929.

https://doi.org/10.1182/blood.V130.Suppl_1.1929.1929

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Blood (2017) 129 (12): 1636–1645.

https://doi.org/10.1182/blood-2016-10-740613

Published: 2017

Includes: Supplemental data

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Jeanette K Doorduijn, MD PhD, Monique C. Minnema, MD PhD, Marie Jose Kersten, MD PhD, Pieternella J Lugtenburg, MD PhD, Martin R. Schipperus, MD PhD, Marinus van Marwijk Kooy, MD PhD, Marius MacKenzie, MD PhD, Josée M Zijlstra, MD, Henriette W Berenschot, MD, M. R Schaafsma, MD PhD, Dana A Chitu, PhD, Hanneke C. Kluin-Nelemans, MD PhD

Blood (2015) 126 (23): 339.

https://doi.org/10.1182/blood.V126.23.339.339

Published: 2015

Journal Articles

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Blood (2015) 126 (23): 27.

https://doi.org/10.1182/blood.V126.23.27.27

Published: 2015

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Pieter Sonneveld, Emilie Asselbergs, Sonja Zweegman, Bronno van der Holt, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Annemiek Broyl, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst

Blood (2015) 125 (3): 449–456.

https://doi.org/10.1182/blood-2014-05-576256

Published: 2015

Includes: Supplemental data

Journal Articles

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Pieter Sonneveld, MDPhD, Emilie Asselbergs, Bronno Van der Holt, PhD, Sonja Zweegman, MDPhD, Marie jose Kerstens, MD, Edo Vellenga, MD PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2014) 124 (21): 2118.

https://doi.org/10.1182/blood.V124.21.2118.2118

Published: 2014

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

Journal Articles

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Pieter Sonneveld, MD, Ph.D, Emilie Asselberg-Hacker, Sonja Zweegman, MD PhD, Bronno van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk Kooy, MD, PhD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2013) 122 (21): 688.

https://doi.org/10.1182/blood.V122.21.688.688

Published: 2013

Journal Articles

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Blood (2012) 120 (24): 4706–4711.

https://doi.org/10.1182/blood-2012-04-420596

Published: 2012

Includes: Supplemental data

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Pieter Sonneveld, MD, Emilie Asselbergs, Sonja Zweegman, MD, PhD, Bronno Van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Henk Lokhorst, MD, PhD

Blood (2012) 120 (21): 333.

https://doi.org/10.1182/blood.V120.21.333.333

Published: 2012

NARROW

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Efficacy of Bone Marrow Derived MSC for Steroid Refractory Acute GVHD Associates with Age and a Defined Molecular Profile of MSC Donors

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only